Experienced in Peptic Ulcer

Saroj K. Sinha

Chandigarh, CH, IN 
Experienced in Peptic Ulcer
Chandigarh, CH, IN 
OverviewLocationsClinical Research

Overview

Saroj Sinha practices in Chandigarh, India. Sinha is rated as an Experienced expert by MediFind in the treatment of Peptic Ulcer. Their top areas of expertise are Acute Pancreatitis, Hereditary Pancreatitis, Necrosis, Endoscopy, and Pancreaticoduodenectomy.

Their clinical research consists of co-authoring 218 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Peptic Ulcer.

Locations

Chandigarh, CH, India
Other Locations
Rishikesh, UL, India
14 Middle Arterial Road, Rajarhat, New Town, Kolkata, WB 700160, India
Kanpur, JK, India
New Delhi, DL, India
PB 160012, India
Climate Change And Forest Influence Division, Forest Research Institute, P.O. New Forest, Dehra Dun, UL 248006, India
Pune, MH 411040, India
Sonamukhi, WB 722207, India

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
Gut-Liver Axis Modulation With IgG-Enriched Immunotherapy in Severe Alcohol-Associated Hepatitis: A Multicentre, Randomised, Placebo-Controlled Trial
Gut-Liver Axis Modulation With IgG-Enriched Immunotherapy in Severe Alcohol-Associated Hepatitis: A Multicentre, Randomised, Placebo-Controlled Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drug: Bovine Colostrum
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
View 3 Less Clinical Trials

218 Total Publications

Impact of Hepatic Steatosis, Psoas Muscle Mass, and Density on Outcomes in Patients with Moderately Severe and Severe Acute Pancreatitis: A Serial Computed Tomography-Based Retrospective Study.
Impact of Hepatic Steatosis, Psoas Muscle Mass, and Density on Outcomes in Patients with Moderately Severe and Severe Acute Pancreatitis: A Serial Computed Tomography-Based Retrospective Study.
Journal: The Indian journal of radiology & imaging
Published: September 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Sinha's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 70 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile